These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19408074)

  • 1. Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.
    Kurt IH
    Surg Today; 2009; 39(5):381-6. PubMed ID: 19408074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia.
    Sonntag S; Sundberg S; Lehtonen LA; Kleber FX
    J Am Coll Cardiol; 2004 Jun; 43(12):2177-82. PubMed ID: 15193677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan preoperative.
    Rognoni A; Lupi A; Cavallino C; Veia A; Bacchini S; Rosso R; Secco GG; Bongo AS
    Curr Pharm Des; 2013; 19(22):3974-8. PubMed ID: 23228313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study.
    Shah B; Sharma P; Brahmbhatt A; Shah R; Rathod B; Shastri N; Patel J; Malhotra A
    Indian J Pharmacol; 2014; 46(1):29-34. PubMed ID: 24550581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of levosimendan in the treatment of heart failure.
    Kasikcioglu HA; Cam N
    Vasc Health Risk Manag; 2006; 2(4):389-400. PubMed ID: 17323593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG; McGowan J
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levosimendan in cardiology and intensive care medicine].
    Delle Karth G; Heinz G
    Wien Klin Wochenschr; 2004 Jan; 116(1-2):6-14. PubMed ID: 15030117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
    Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levosimendan in regional myocardial ischemia.
    Pieske B
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):379-81. PubMed ID: 12656119
    [No Abstract]   [Full Text] [Related]  

  • 12. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts.
    Rump AF; Acar D; Rösen R; Klaus W
    Pharmacol Toxicol; 1994; 74(4-5):244-8. PubMed ID: 8090694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan: a promising treatment for myocardial stunning?
    Ellger BM; Zahn PK; Van Aken HK; Schmidt C; Brussel T
    Anaesthesia; 2006 Jan; 61(1):61-3. PubMed ID: 16409345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: a novel agent in heart failure.
    Koumallos N; Antoniades C; Tousoulis D; Shirodaria C; Stefanadis C
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan use in several scenarios of acute heart failure.
    Tavares M; Andrade AC; Mebazaa A
    Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
    Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
    Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion.
    Eriksson O; Pollesello P; Haikala H
    J Cardiovasc Pharmacol; 2004 Sep; 44(3):316-21. PubMed ID: 15475828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.